

Overview

- 3100 participants
- 10 sites
- 4 provinces
- 5 health networks
- 6 cancer types

PMT Portal Development

The next release of the PMT Portal (PMT05/06) will incorporate a new functionality: a specimen management module to coordinate and track specimen collection, shipments and processing. The PMT Agents Team will participate in user testing of this module during the month of January 2019. We plan to implement the release by March 2019.

PMT Agent Team Meeting

The PMT Agent Team met on December 3rd. The team provided recommendations for the next face to face meeting, recruitment, the PMT Portal dashboard and the plan for testing upcoming releases.

Season's Greetings and Holiday Closure

Exactis Innovation would like to wish everyone a happy holiday! Our office will be closed from December 22nd to January 6th.




Fabrice Yoboua
fyoboua@exactis.ca

PMT Face to Face Meeting



The face to face meeting on September 21st was a resounding success. 17 PMT agents from 8 sites got together with members of Exactis to discuss challenges relating to genetic testing and to PMT in general, to share best practices on participant recruitment and site-specific strategies, to receive updates from Exactis, and to exchange feedback.

PMT Recruitment and Breakdown by Cancer Type



Congratulations to the CHUM for having recruited 1000 patients!



Thanks to the team: Alexandria Aubourg, Renée Bernatchez, Julie Bilodeau, Geneviève Cormier, Sophie Langevin, Stéphanie Lepage, Julie Malo, Dr Anne-Marie Mes-Masson, Adriana Orimoto, Louise Rousseau, Dr Fred Saad, Claudia Syed, Dr Simon Turcotte (pictured with members of Exactis).

Innovation Exactis
5450 Ch. Côte-des-Neiges #522
Montréal, QC H3T 1Y6



Garyfallia (Rosa) Christodouloupoulos
gchristod@exactis.ca



Investigator-Initiated Trial Competition

In 2019, Exactis Innovation will announce a competition that will award \$1M to fund an interventional precision oncology investigator-initiated clinical trial in the Exactis Network. A successful proposal will be expected to describe a collaboration between investigators from at least three Exactis Network sites and to test novel ideas in precision oncology by leveraging outstanding Canadian clinical expertise. Proposals will be eligible for in-kind study management support from Exactis' Clinical Operations team and will be expected to provide a sponsor commitment for the trial's therapeutic agent/intervention. Detailed criteria, requirements and timelines will follow with a formal competition announcement and a call for letters of intent in January 2019.

Introducing the Newest Member of the Exactis Team



Andrew Slack is excited to join Exactis Innovation as its new Director of Medical Affairs. In this role, Andrew looks forward to close collaboration with members of the Exactis Principal Investigators Coordinating Committee (PICC).

One of Andrew's most important objectives is to increase awareness of PMT with Exactis Network site PIs in order to help support the activities of our PMT Agents.

Commitment to Equity, Diversity and Inclusion

At Exactis, equity, diversity and inclusion (EDI) are an integral part of our culture and mission. EDI are tangible values for us! Thus, Exactis has developed an EDI strategy that was approved by its Board of Directors to enhance EDI values within its workforce, the PMT research network, the composition of its research and scientific committees and the Board of Directors. A copy of the Exactis EDI strategy is available upon request.

Clinical Trials

Exactis is currently managing the following trials.

QCROC-01 ([NCT00984048](#))

Q-CROC-01 is a prospective study to identify biomarkers of resistance or response to standard first line therapy in patients with metastatic colorectal cancer (mCRC). The study is in the final analysis and a manuscript is in preparation. This will be the largest mCRC cohort profiled and it provides an unprecedented view of mCRC at the copy number variation level. Additionally, Dr. Turcotte (CHUM) defined a relatively high level of expression of immune transcripts in a sub-group of mCRC from our RNAseq Q-CROC-01.

QCROC-05 ([NCT02041468](#))

Q-CROC-05 is a phase IV study to evaluate proteogenomic biomarkers predictive of response to crizotinib in metastatic ALK+ NSCLC patients. This study has identified a putative protein signature that may predict long-term response to crizotinib. To our knowledge, this is the first report of a blood-based proteomic signature predicting response in ALK+ NSCLC treated with an ALK-TKI. We are looking for potential collaborators to confirm the validity of this protein signature in a larger cohort, and with next-generation ALK-TKIs. A manuscript focusing on the genomic analysis will be submitted by the end of 2018.

QCROC-06 ([NCT01949194](#))

Q-CROC-06 is a phase II prospective study to determine the efficacy of regorafenib as single-agent treatment for second-line metastatic colorectal cancer and to identify predictive biomarkers. Patients are asked to undergo a biopsy of a metastatic lesion prior to treatment, and an optional liver biopsy at the time of relapse. Using several next generation discovery platforms, biomarkers will be identified in the metastatic tumour specimens and in blood samples collected throughout the treatment. 48 patients were enrolled and biomarker analysis is ongoing.

TRAM-01 ([NCT03363217](#))

TRAM-01 is a phase II study in patients with pediatric low-grade glioma or plexiform neurofibroma with refractory tumour and activation of the MAPK/ERK pathway who are treated with trametinib monotherapy. Four sites are actively recruiting patients since August 2018. Another two sites are expected to open in Q1 2019. To date 13 of 150 patients have been enrolled.